Supplementation of Non-Fermented and Fermented Red Ginseng Improves Obese Phenotypes, Lipid and Inflammatory Profiles, and Antioxidant Defense System in High Fat-Fed Rats

Soyeon Jeong¹, Misun Park¹, Minji Kang¹, Yeong-Ju Park¹, Minkyeong Lee¹, Cheongbin You¹, Unsik Hwang¹, Youngju Song², Hoon Park¹, Sunhye Lee^1, and Heejae Suh^1,

¹Research Center for Food and Bio Convergence, Department of Food Science, Sun Moon University, Asan, Chungchengnam-do, 31460, Republic of Korea

²Institute of Sports Health Science, Sun Moon University, Asan, Chungchengnam-do, 31460, Republic of Korea

Cite this paper:
Soyeon Jeong, Misun Park, Minji Kang, Yeong-Ju Park, Minkyeong Lee, Cheongbin You, Unsik Hwang, Youngju Song, Hoon Park, Sunhye Lee and Heejae Suh. Supplementation of Non-Fermented and Fermented Red Ginseng Improves Obese Phenotypes, Lipid and Inflammatory Profiles, and Antioxidant Defense System in High Fat-Fed Rats. Journal of Food and Nutrition Research. 2021; 9(3):154-162. doi: 10.12691/jfnr-9-3-8

Abstract

Obesity is characterized by excessive fat accumulation, chronic inflammation, and enhanced oxidative stress that can present a substantial risk for metabolic complications. The aim of this study was to investigate the protective effects of red ginseng (RG), and its bio-transformed form (fermented RG, FRG) by microorganism on obese phenotype, lipid profile, and inflammation and oxidant profiles in rats fed a high-fat (HF) diet. FRG was prepared by fermentation of RG with Lactobacillus pentosus KCCM 12762P. Male Sprague-Dawley rats (n = 8/group; 6 weeks old) were counterbalanced by initial weight into four groups and fed either a low-fat (LF; 10% kcal as fat), high-fat (HF; 45% kcal as fat), or HF diet supplemented with RG or FRG at 1% (w/w) in diet for 6 weeks. General phenotypes (body weight, energy intake, visceral adiposity), lipid and inflammatory profiles, and oxidative states were assessed. RG and FRG supplementation suppressed HF-induced upregulation of proinflammatory cytokine genes, interleukin-6 and tumor necrosis factor alpha, in both white adipose and liver tissues. Similarly, RG and FRG partially reversed HF-induced downregulation of antioxidant enzymes at the gene level. Concomitantly, RG and FRG reduced body weight gain, energy intake, visceral adiposity and the level of serum triglycerides. It is of note that better metabolic profile was observed with FRG than RG for lipid metabolism and inflammation, in the liver in particular. Taken together, we demonstrated that RG and FRG supplementation effectively protected from HF-induced metabolic disturbances by improving obese phenotypes, lipid and inflammatory profiles, and antioxidant defense system.

Keywords:
red ginseng fermented red ginseng inflammation oxidative stress dyslipidemia diet-induced obesity

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	“World health organization. global strategy on diet physical activity and health. what is overweight and obesity? [online]. Available: Http://www.who.int/dietphysicalactivity/childhood_what/en/. [Accessed Dec. 2020]
[2]	Pedersen, S.D. “Metabolic complications of obesity”, Best Practice & Research Clinical Endocrinology & Metabolism, 27 (2). 179-93. Apr.2013.
[3]	Cancello, R., Tordjman J., Poitou C., Guilhem G., Bouillot J.L., Hugol D., Coussieu C., Basdevant A., Hen A.B., Bedossa P., “Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity”, Diabetes, 55 (6). 1554-61. Jun.2006.
[4]	Burhans, M.S., Hagman D.K., Kuzma J.N., Schmidt K.A., Kratz M., “Contribution of adipose tissue inflammation to the development of type 2 diabetes mellitus”, Comprehensive Physiology, 9 (1). 1-58. Jan.2011.
[5]	Fernández-Sánchez, A., Madrigal-Santillán E., Bautista M., Esquivel-Soto J., Morales-González Á, Esquivel-Chirino C., Durante-Montiel I., Sánchez-Rivera G., Valadez-Vega C., Morales-González J.A., “Inflammation, oxidative stress, and obesity”, International Journal of Molecular Sciences, 12 (5). 3117-32. May.2011.
[6]	Albenberg, L.G., Wu G.D., “Diet and the intestinal microbiome: associations, functions, and implications for health and disease”, Gastroenterology, 146 (6). 1564-72. May.2014.
[7]	Yun, J.W. “Possible anti-obesity therapeutics from nature–A review”, Phytochemistry, 71 (14-15). 1625-41. Oct.2010.
[8]	Lee, S., Keirsey K.I., Kirkland R., Grunewald Z.I., Fischer J.G., de La Serre, Claire B, “Blueberry supplementation influences the gut microbiota, inflammation, and insulin resistance in high-fat-diet–fed rats”, The Journal of Nutrition, 148 (2). 209-19. Feb.2018.
[9]	Lee, S., Kirkland R., Grunewald Z.I., Sun Q., Wicker L., de La Serre, Claire B, “Beneficial Effects of Non-Encapsulated or Encapsulated Probiotic Supplementation on Microbiota Composition, Intestinal Barrier Functions, Inflammatory Profiles, and Glucose Tolerance in High Fat Fed Rats”, Nutrients, 11 (9). 1975. Sep.2019.
[10]	Lee, S., Goodson M., Vang W., Kalanetra K., Barile D., Raybould H., “2′-Fucosyllactose Supplementation Improves Gut-Brain Signaling and Diet-Induced Obese Phenotype and Changes the Gut Microbiota in High Fat-Fed Mice”, Nutrients, 12 (4). 1003. Apr.2020.
[11]	Coon, J.T., Ernst E., “Panax ginseng”, Drug Safety, 25 (5). 323-44. Apr.2002.
[12]	Kim, J. “Cardiovascular diseases and Panax ginseng: a review on molecular mechanisms and medical applications”, Journal of Ginseng Research, 36 (1). 16. Jan.2012.
[13]	Li, Z., Ji G.E., “Ginseng and obesity”, Journal of Ginseng Research, 42 (1). 1-8. Jan.2018.
[14]	Hasegawa, H. “Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside: deglycosylation by intestinal bacteria and esterification with fatty acid”, Journal of Pharmacological Sciences, 95 (2). 153-7. Jan. 2004.
[15]	Jung, H., Choi H., Lim H., Shin D., Kim H., Kwon B., Lee J.E., Park E., Lim C., “Enhancement of anti‐inflammatory and antinociceptive actions of red ginseng extract by fermentation”, Journal of Pharmacy and Pharmacology, 64 (5). 756-62. May. 2012.
[16]	Trinh, H., Han S., Kim S., Lee Y., Kim D., “Bifidus fermentation increases hypolipidemic and hypoglycemic effects of red ginseng”, Journal of Microbiology and Biotechnology, 17 (7). 1127-33. Mar. 2007.
[17]	Kho, M.C., Lee Y.J., Park J.H., Kim H.Y., Yoon J.J., Ahn Y.M., Tan R., Park M.C., Cha J.D., Choi K.M., “Fermented red ginseng potentiates improvement of metabolic dysfunction in metabolic syndrome rat models”, Nutrients, 8 (6). 369. Jun. 2016.
[18]	Sharma, A., Lee H., “Ginsenoside compound k: insights into recent studies on pharmacokinetics and health-promoting activities”, Biomolecules, 10 (7). 1028. Jul. 2020.
[19]	Igami, K., Shimojo Y., Ito H., Miyazaki T., Kashiwada Y., “Hepatoprotective effect of fermented ginseng and its major constituent compound K in a rat model of paracetamol (acetaminophen)-induced liver injury”, Journal of Pharmacy and Pharmacology, 67 (4). 565-72. Apr. 2015.
[20]	Kim, B., Choi S., Kim M., Suh H.J., Park H.J., “Changes of ginsenosides in Korean red ginseng (Panax ginseng) fermented by Lactobacillus plantarum M1”, Process Biochemistry, 45 (8). 1319-24. Aug. 2010.
[21]	Kim, J.H., Doo E., Jeong M., Kim S., Lee Y., Yang J., Lee J.S., Kim J.H., Lee K.W., Huh C.S., “Enhancing immunomodulatory function of red Ginseng through fermentation using Bifidobacterium animalis Subsp. lactis LT 19-2”, Nutrients, 11 (7). 1481. Jul. 2019.
[22]	Jung, J., Jang H.J., Eom S.J., Choi N.S., Lee N., Paik H., “Fermentation of red ginseng extract by the probiotic Lactobacillus plantarum KCCM 11613P: ginsenoside conversion and antioxidant effects”, Journal of Ginseng Research, 43 (1). 20-6. Jan.2019.
[23]	Park, Y., Park, S., Sim, S., Jeong, S., Park, M., Kang, M., Lee, Y., Song, Y., Park, H., Suh, H. “Optimal bioconversion for compound K production from red ginseng root (C.A. Mayer) by sequential enzymatic hydrolysis and its characteristics”, Applied Biological Chemistry. In Press.
[24]	Zhou, W., Li J., Li X., Yan Q., Zhou P., “Development and validation of a reversed‐phase HPLC method for quantitative determination of ginsenosides Rb1, Rd, F2, and compound K during the process of biotransformation of ginsenoside Rb1”, Journal of Separation Science, 31 (6‐7). 921-5. Apr.2008.
[25]	Livak, K.J., Schmittgen T.D., “Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method”, Methods, 25 (4). 402-8. Dec.2001.
[26]	Park, S., Park J., Kim H., Lee C., Lee H., Kang K.S., Kim C., “Systems-level mechanisms of action of Panax ginseng: a network pharmacological approach”, Journal of Ginseng Research, 42 (1). 98-106. Jan.2018.
[27]	Park, Y., Lim J., Kim J., Lee S., “Review of Red Ginseng in terms of Mechanisms for Pharmacodynamics and Toxicity”, The Journal of Korean Medicine, 33 (3). 200-30. Sep.2012.
[28]	Yang, X., Yang Y., Ouyang D., Yang G., “A review of biotransformation and pharmacology of ginsenoside compound K”, Fitoterapia, 100 208-20. 2015.
[29]	Lee, J., Lee E., Kim D., Lee J., Yoo J., Koh B., “Studies on absorption, distribution and metabolism of ginseng in humans after oral administration”, Journal of Ethnopharmacology, 122 (1). 143-8. Jan.2009.
[30]	Kim, E.H., Lim S., Kim S.O., Ahn S.H., Choi Y.J., “Optimization of enzymatic treatment for compound K production from white ginseng extract by response surface methodology”, Bioscience, Biotechnology, and Biochemistry, 120823. May.2013.
[31]	Zheng, M., Xu F., Li Y., Xi X., Cui X., Han C., Zhang X., “Study on transformation of ginsenosides in different methods”, BioMed Research International, 2017. Dec.2017.
[32]	Kim, C.M., Yi S.J., Cho I.J., Ku S.K., “Red-koji fermented red ginseng ameliorates high fat diet-induced metabolic disorders in mice”, Nutrients, 5 (11). 4316-32. Nov.2013.
[33]	Li, Z., Kim H.J., Park M.S., Ji G.E., “Effects of fermented ginseng root and ginseng berry on obesity and lipid metabolism in mice fed a high-fat diet”, Journal of Ginseng Research, 42 (3). 312-9. Jul.2018.
[34]	Knebel, B., Haas J., Hartwig S., Jacob S., Köllmer C., Nitzgen U., Muller–Wieland D., Kotzka J., “Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass”, PloS One, 7 (2). e31812. Feb.2012.
[35]	Lee, Y., Cha B., Yamaguchi K., Choi S., Yonezawa T., Teruya T., Nagai K., Woo J., “Effects of Korean white ginseng extracts on obesity in high-fat diet-induced obese mice”, Cytotechnology, 62 (4). 367-76. Aug.2010.
[36]	Klop, B., Elte J.W.F., Cabezas M.C., “Dyslipidemia in obesity: mechanisms and potential targets”, Nutrients, 5 (4). 1218-40. Apr.2013.
[37]	Kwak, Y., Kyung J., Kim J.S., Cho J.Y., Rhee M., “Anti-hyperlipidemic effects of red ginseng acidic polysaccharide from Korean red ginseng”, Biological and Pharmaceutical Bulletin, 33 (3). 468-72. Mar.2010.
[38]	Longo, M., Zatterale F., Naderi J., Parrillo L., Formisano P., Raciti G.A., Beguinot F., Miele C., “Adipose tissue dysfunction as determinant of obesity-associated metabolic complications”, International Journal of Molecular Sciences, 20 (9). 2358. Jan.2019.
[39]	Suh, D.H., Jung E.S., Park H.M., Kim S.H., Lee S., Jo Y.H., Lee M.K., Jung G., Do S., Lee C.H., “Comparison of metabolites variation and antiobesity effects of fermented versus nonfermented mixtures of Cudrania tricuspidata, Lonicera caerulea, and soybean according to fermentation in vitro and in vivo”, PloS One, 11 (2). e0149022. Feb.2016.
[40]	Han, C., Wei H., Guo J., “Anti-inflammatory effects of fermented and non-fermented Sophora flavescens: a comparative study”, BMC Complementary and Alternative Medicine, 11 (1). 1-6. Dec.2011.
[41]	Jin, H., Seo J., Uhm Y., Jung C., Lee S., Yim S., “Pharmacokinetic comparison of ginsenoside metabolite IH-901 from fermented and non-fermented ginseng in healthy Korean volunteers”, Journal of Ethnopharmacology, 139 (2). 664-7. Jan. 2012.